Letters by company
Zimmer Biomet Holdings, INC.
4 letters discussing ZBH. Everything written about it on this site is on its ticker page.
- Long Cast Advisers 2Q26 PDEX remains a top position because Zimmer’s mBos launch could materially expand its operating cash flow. Long Cast added to NRC on its record contract backlog and management transition, while monitoring PESI’s Hanford waste-processing opportunity and expecting MTRX’s cash earnings to exceed market expectations. The portfolio exited acquired CCRN and added to QRHC. 2Q26 NRC $565MZBH $20B
- Long Cast Advisers 3Q26 Pro-Dex remains the largest holding, with Long Cast expecting its role in Zimmer’s robotic knee platform and contingent-value-right milestones to broaden growth and customer diversification. Matrix Service is retained on the view that new leadership, lower costs, backlog and a buyback can reset investor expectations. Research Solutions is developing publisher-IP and enterprise AI products as the manager argues paywalled data may become more valuable. 3Q26 IT $12BMTRX $260MPDEX $216M
- SRK Capital 2026 H1 Partnership Letter SRK Fund I avoided AI-buildout companies, favoring neglected businesses with visible cash flows, aligned operators and scope for operational improvement. The portfolio added Pro-Dex after its key customer contract renewal, exited Sanuwave over weakening wound-care customer economics, and retained ImmuCell and Outdoor Holding on improving earnings and cash-generation prospects. first half of 2026 ICCC $93MPDEX $216MPOWW $268M
- Long Cast Advisers 1Q26 Long Cast added to National Research Corporation and Cross Country Healthcare, then took gains in Cross Country Healthcare after its acquisition announcement. It exited Enovix, Richardson Electronics and Crawford United, while arguing that Matrix Service, Pro-Dex and Mama’s Creations have operational catalysts. The manager views Research Solutions as an AI-enabled information-services business rather than an AI casualty. 1Q26 MAMA $624MMTRX $260MPDEX $216M
